Class Action Lawsuit Announced for Atara Biotherapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATRA?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Atara Biotherapeutics (NASDAQ: ATRA) securities purchasers from May 20, 2024, to January 9, 2026, with a deadline of May 22, 2026, for investors to apply as lead plaintiffs to represent other members in the litigation.
- Potential Compensation Opportunity: Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Lawsuit Details Disclosure: The lawsuit alleges that Atara made false or misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which could significantly impact the company's financial condition, leading to investor losses once the truth emerged.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.710
Low
18.00
Averages
21.50
High
25.00
Current: 4.710
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Atara Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Atara Biotherapeutics, Inc. for potential claims related to investor losses incurred from May 20, 2024, to January 9, 2026, indicating significant legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely legal action to protect their rights.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact options, which demonstrates the firm's commitment to supporting victims.
- Potential Litigation Impact: Should the investigation reveal wrongdoing by Atara, the company may face substantial financial liabilities, potentially affecting its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Atara Biotherapeutics (NASDAQ: ATRA) securities purchasers from May 20, 2024, to January 9, 2026, with a deadline of May 22, 2026, for investors to apply as lead plaintiffs to represent other members in the litigation.
- Potential Compensation Opportunity: Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Lawsuit Details Disclosure: The lawsuit alleges that Atara made false or misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which could significantly impact the company's financial condition, leading to investor losses once the truth emerged.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The lawsuit alleges that Atara made false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, particularly concerning manufacturing issues affecting the FDA approval prospects of tabelecleucel.
- Potential Impact: The identified manufacturing deficiencies and issues within the ALLELE study expose Atara to increased regulatory scrutiny, which could significantly jeopardize its ongoing clinical trials and overall financial health.
- Investor Rights: Affected investors have until May 22, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Lawsuit Overview: Lufax Holding Ltd. is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, potentially impacting the company's reputation and stock price.
- Atara Biotherapeutics Issues: Atara Biotherapeutics, Inc. is under scrutiny for not disclosing manufacturing problems and clinical trial risks from May 20, 2024, to January 9, 2026, leading to investor misjudgment regarding its FDA approval prospects, with a lead plaintiff deadline of May 22, 2026, which could negatively affect future financing and market confidence.
- Coty Performance Decline: Coty Inc. faces a class action lawsuit due to underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, likely putting pressure on the company's stock price and investor confidence.
- Super Micro Compliance Risks: Super Micro Computer, Inc. is involved in a class action lawsuit for failing to comply with U.S. export control laws from April 30, 2024, to March 12, 2026, with a lead plaintiff deadline of May 26, 2026, which may significantly impact the company's future compliance costs and market image.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor trust.
- FDA Response Letter: On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter regarding its tabelecleucel BLA, stating that the current trial design is inadequate for accelerated approval, resulting in a 56.99% drop in stock price to $5.88 per share, indicating a direct impact of regulatory risks on the company's financial health.
- Increased Regulatory Risks: The lawsuit alleges that Atara misled investors about its drug candidate's regulatory prospects, particularly due to manufacturing issues and deficiencies in the ALLELE study, significantly lowering the likelihood of FDA approval and heightening investor concerns about the company's future.
- Shareholder Rights Protection: Robbins LLP offers contingency-based representation, allowing shareholders to submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, demonstrating the firm's commitment to protecting shareholder interests and accountability in corporate governance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- FDA Regulatory Risks: Atara's Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials.
- Stock Price Volatility: Following the CRL on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, and further declined by 7.91% to $6.05 per share on January 21, 2025, due to a clinical hold, indicating severe market pessimism regarding the company's future.
- Uncertain Regulatory Outlook: On January 12, 2026, Atara received another CRL indicating that the ALLELE trial's design and analysis were inadequate for FDA approval, leading to a 56.99% drop in stock price to $5.88 per share, highlighting significant financial and operational challenges ahead for the company.
See More
Faruqi & Faruqi Investigates Atara Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Atara Biotherapeutics, Inc. for potential claims related to investor losses incurred from May 20, 2024, to January 9, 2026, indicating significant legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely legal action to protect their rights.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact options, which demonstrates the firm's commitment to supporting victims.
- Potential Litigation Impact: Should the investigation reveal wrongdoing by Atara, the company may face substantial financial liabilities, potentially affecting its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Atara Biotherapeutics (NASDAQ: ATRA) securities purchasers from May 20, 2024, to January 9, 2026, with a deadline of May 22, 2026, for investors to apply as lead plaintiffs to represent other members in the litigation.
- Potential Compensation Opportunity: Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Lawsuit Details Disclosure: The lawsuit alleges that Atara made false or misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which could significantly impact the company's financial condition, leading to investor losses once the truth emerged.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The lawsuit alleges that Atara made false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, particularly concerning manufacturing issues affecting the FDA approval prospects of tabelecleucel.
- Potential Impact: The identified manufacturing deficiencies and issues within the ALLELE study expose Atara to increased regulatory scrutiny, which could significantly jeopardize its ongoing clinical trials and overall financial health.
- Investor Rights: Affected investors have until May 22, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Lawsuit Overview: Lufax Holding Ltd. is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, potentially impacting the company's reputation and stock price.
- Atara Biotherapeutics Issues: Atara Biotherapeutics, Inc. is under scrutiny for not disclosing manufacturing problems and clinical trial risks from May 20, 2024, to January 9, 2026, leading to investor misjudgment regarding its FDA approval prospects, with a lead plaintiff deadline of May 22, 2026, which could negatively affect future financing and market confidence.
- Coty Performance Decline: Coty Inc. faces a class action lawsuit due to underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, likely putting pressure on the company's stock price and investor confidence.
- Super Micro Compliance Risks: Super Micro Computer, Inc. is involved in a class action lawsuit for failing to comply with U.S. export control laws from April 30, 2024, to March 12, 2026, with a lead plaintiff deadline of May 26, 2026, which may significantly impact the company's future compliance costs and market image.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor trust.
- FDA Response Letter: On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter regarding its tabelecleucel BLA, stating that the current trial design is inadequate for accelerated approval, resulting in a 56.99% drop in stock price to $5.88 per share, indicating a direct impact of regulatory risks on the company's financial health.
- Increased Regulatory Risks: The lawsuit alleges that Atara misled investors about its drug candidate's regulatory prospects, particularly due to manufacturing issues and deficiencies in the ALLELE study, significantly lowering the likelihood of FDA approval and heightening investor concerns about the company's future.
- Shareholder Rights Protection: Robbins LLP offers contingency-based representation, allowing shareholders to submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, demonstrating the firm's commitment to protecting shareholder interests and accountability in corporate governance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- FDA Regulatory Risks: Atara's Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials.
- Stock Price Volatility: Following the CRL on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, and further declined by 7.91% to $6.05 per share on January 21, 2025, due to a clinical hold, indicating severe market pessimism regarding the company's future.
- Uncertain Regulatory Outlook: On January 12, 2026, Atara received another CRL indicating that the ALLELE trial's design and analysis were inadequate for FDA approval, leading to a 56.99% drop in stock price to $5.88 per share, highlighting significant financial and operational challenges ahead for the company.
See More
